Drugs / Livact Granule
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07634523 | Feb 2025 → May 2027 expected | muscular atrophy | Seoul National University Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Livact Granule | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07634523 ↗ |
| Route | Oral | “Livact granules 4.15 g are administered orally, one packet three times daily after meals for 3 months after total knee arthroplasty.” NCT07634523 ↗ |